NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial Average gained 0.29 percent to close at 24,597.38, while the S&P 500 Index fell 0.02 percent to close at 2,650.54. The Nasdaq Composite Index dropped 0.39 percent to close at 7,070.33.
“Trade tensions between the U.S. and China is the biggest factor creating volatility,” said the president of Caliber Financial Partners, Patrick Healey. “Investors are clinging to the recent positive news about trade negotiations, but we won’t see the end of this volatility until there is a concrete agreement in place,” Healey added.
The Market Edge Initiates Coverage on:
Sage Therapeutics, Inc.
Sage Therapeutics’ stock moved 9.06% lower Thursday, to close the day at $100.62. The stock recorded a trading volume of 495,289 shares, which was above its three months average volume of 413,631 shares. In the last year, Sage Therapeutics’ shares have traded in a range of 100.16 - 195.97. The share price has gained 0.46% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $116.45 is below its 200-day moving average of $141.93. Shares of Sage Therapeutics have fallen roughly 7.71 percent in the past month and are down 38.91 percent year-to-date.
Access The Market Edge's Sage Therapeutics, Inc. Research Report:
On Thursday, shares of Altimmune recorded a trading volume of 1,532,482 shares, which was above the three months average volume of 1,153,788 shares. The stock ended the day 20.98% lower at $2.41. The share price has fallen 96.35% from its 52 week high with a 52 week trading range of 2.33 - 66.00. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.54 is below its 200-day moving average of $9.34. Shares of Altimmune have fallen roughly 29.12 percent in the past month and are down 95.96 percent year-to-date.
Access The Market Edge's Altimmune, Inc. Research Report:
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: The Market Edge